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Abstract 
Paravalvular leak (PVL) following transcatheter aortic valve replacement (TAVR) is associated 
with worse long-term outcomes. The Lotus Valve incorporates an innovative adaptive seal 
designed to minimize PVL. This analysis evaluated the incidence and predictors of PVL 
following implantation of the Lotus transcatheter aortic valve. The REPRISE II study with 
Extended Cohort enrolled 250 high-surgical risk patients with severe symptomatic aortic 
stenosis. Aortic regurgitation was assessed by echocardiography pre-procedure, at discharge and 
30 days by an independent core lab. Baseline and procedural predictors of mild or greater PVL at 
30 days (or at discharge if 30-day data were not available) were determined using a multivariate 
regression model (N=229). Among 229 patients, 197 (86%) had no/trace PVL, 30 had mild, and 
2 had moderate PVL; no patient had severe PVL. Significant predictors of mild/moderate PVL 
included device:annulus area ratio (odds ratio [OR]: 0.87 (95% CI: 0.83-0.92); P<0.001), LVOT 
calcium volume (OR:2.85;(1.44-5.63); P=0.003), and annulus area (OR:0.89(0.82-0.96); 
P=0.002). When the device:annulus area ratio was <1, the rate of mild/moderate PVL was 53.1% 
(17/32). The rates of mild/moderate PVL with 0-5%, 5-10%, and >10% annular oversizing by 
area were 17.5% (11/63), 2.9% (2/70), and 3.2% (2/63), respectively. Significant independent 
predictors of PVL included device:annulus area ratio and LVOT calcium volume. When the 
prosthetic valve was oversized by ≥5%, the rate of mild or greater PVL was only 3%. In 
conclusion, the overall rates of PVL with the Lotus Valve are low and predominantly related to 
device/annulus areas and calcium; these findings have implications for optimal device sizing. 
Key Words:  aortic valve stenosis, transcatheter aortic valve implantation, clinical trial, 
paravalvular regurgitation  
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Paravalvular leak (PVL) is a significant predictor of mortality following transcatheter 
aortic valve replacement (TAVR).1 Reported predictors of PVL post-implantation with first-
generation transcatheter aortic valves include annulus/device size mismatch; annulus 
eccentricity2; excessive calcification in the annulus, leaflets or left ventricular outflow tract 
(LVOT); device implantation depth; baseline aortic or mitral regurgitation; baseline atrial 
fibrillation; and valve choice (CoreValve versus Sapien).3-6 The Lotus Aortic Valve (Boston 
Scientific, Marlborough, MA, USA) incorporates an innovative Adaptive Seal™ designed to 
minimize PVL. Although the overall incidence of PVL with the Lotus valve is low, mild PVL 
has been reported in up to 10-15% of patients at 30 days.7,8 The objective of this analysis was to 
assess patient, anatomic, and procedural characteristics that predicted PVL following TAVR 
with the Lotus Valve in the REPRISE II Study with Extended Cohort. 
Methods 
Key features of the Lotus Valve (Boston Scientific, Marlborough, MA, USA) are shown 
in Figure 1. The valve incorporates bovine pericardium leaflets into a woven nitinol frame and 
has a central radiopaque marker to enable precise positioning. An Adaptive Seal™ at the base of 
the valve is designed to prevent PVL by sealing paravalvular interstices between the concentric 
valve frame and eccentric anatomy. The Lotus Valve is deployed via controlled mechanical 
expansion, with no rapid pacing required, and functions early in the deployment cycle to 
facilitate hemodynamic stability. The valve is repositionable and fully retrievable even after full 
deployment, allowing assessment of paravalvular regurgitation and the need for repositioning if 
necessary. Two valve sizes, 23mm and 27mm, were available for use in this study. Balloon pre-
dilatation was mandated in the study protocol. 
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The REPRISE II study design and methods have been previously described 7,8. In brief, 
the REPRISE II Study Extended Cohort was a prospective, single-arm, multicenter trial designed 
to evaluate the safety and performance of the Lotus Valve System for the treatment of patients 
with symptomatic aortic stenosis. Patients aged ≥70 years with New York Heart Association 
(NYHA) functional class ≥II, and a baseline aortic annulus size ≥20mm but ≤27mm were 
considered eligible for enrollment if they had a Society of Thoracic Surgery (STS) Score ≥8% or 
were deemed to be at high surgical risk by the local Heart Team due to comorbidities or frailty. 
All Heart Team assessments were confirmed by a central case review committee prior to 
enrollment. One-hundred and twenty patients were enrolled into the original REPRISE II trial, 
and an additional 130 patients were enrolled in the Extended Cohort for a total of 250 patients. 
Patients were enrolled between October 2012 and April 2014 at 20 sites in Europe and Australia. 
Follow-up occurred post-procedure, at hospital discharge or 7 days (whichever came first), and 
30 days. Follow-up will continue at 3 and 6 months, and then annually through 5 years.  
The primary performance endpoint for the first 120 patients enrolled in REPRISE II was 
the mean aortic valve pressure gradient at 30 days, as adjudicated by an independent core 
laboratory. The primary safety endpoint for the REPRISE II trial Extended Cohort was the rate 
of 30-day all-cause mortality.9,10 Anatomic measures at baseline, including aortic valve 
dimensions and calcification, were assessed by computed tomography (CT) in end-systole using 
a pre-determined standardized system (3mensio Medical Imaging BV, Bilthoven, The 
Netherlands). Paravalvular leak was assessed by echocardiography at baseline, discharge, and 30 
days according to VARC-2 criteria.9,10 Independent core labs analyzed both CT (Beth Israel 
Deaconess Medical Center, Boston, USA) and echocardiographic (MedStar, Washington DC, 
USA) results.  An independent clinical events committee adjudicated all adverse clinical events.  
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An Institutional Review Board or Ethics Committee approved the protocol at each site 
prior to patient enrollment. All patients provided written informed consent. The study complied 
with the principles set forth in the Declaration of Helsinki, and is registered at 
www.clinicaltrials.gov under the identifier NCT01627691.  
Patient baseline and procedural characteristics were compared for patients with and 
without mild or greater PVL at 30 days (or at hospital discharge if 30-day data were not 
available) using a 2-sided chi-square or Fisher exact test for categorical variables, as appropriate, 
and Student t tests for continuous variables. Values were expressed as mean ± standard deviation 
for continuous variables and percent (n/N) for categorical variables. Clinical, anatomic, 
electrocardiographic, and procedural characteristics were evaluated as predictors of mild or 
greater PVL by multivariate analysis; these factors were assessed by logistic regression with 
Wald’s chi-square test and expressed as odds ratios with 95% confidence intervals. Significance 
was defined as P<0.05. Statistical analysis was performed using SAS® software version 9.2 or 
above (SAS Institute, Cary, North Carolina, USA). 
Results 
Two-hundred and fifty patients were enrolled in the REPRISE II trial Extended Cohort 
(Figure 2). A total of 243 (97.2%) patients underwent clinical follow-up at hospital discharge or 
7 days (7 patients died prior to discharge), and 228 (91.2%) patients had TTE assessment at 
discharge, of which 201 were considered evaluable for PVL by the core laboratory. For clinical 
follow-up at the primary endpoint of 30 days, 1 patient withdrew consent at day 11, and 3 
patients missed the 30-day follow-up visit with no later follow-up performed, for a total clinical 
follow-up or death rate of 98.4% (246/250). Thirty-day TTE assessment was performed in 215 
patients, of which 177 were considered evaluable for PVL by the core laboratory. 
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Discharge/7-day PVL data were incorporated into the analysis for those patients who did 
not have available 30-day PVL data; this resulted in a total of 229 patients with evaluable 
echocardiograms (Figure 2), of whom 183 (79.9%) had no PVL, 14 (6.1%) had trace PVL, 30 
(13.1%) had mild PVL, and 2 (0.9%) had moderate PVL, and thus comprised the analysis 
population for this manuscript (Figure 3). 
Baseline patient and anatomic characteristics of patients with and without ≥mild PVL at 
discharge/30 days are shown in Table 1. Patients with ≥mild PVL were significantly more likely 
to be older, female, have medically treated hyperlipidemia, and have a higher pre-procedure 
mean aortic gradient. Calcium volume in the LVOT and annulus/leaflets was also significantly 
greater in patients with ≥mild PVL, particularly with regard to the LVOT (70.6±9.4mm2 vs 
22.4±43.3mm2 no PVL; P=0.008). 
Procedural factors for patients with and without ≥mild PVL are shown in Table 2. 
Compared to patients with no PVL, patients with ≥mild PVL were significantly more likely to 
have received the 23mm valve, to have a lower ratio of the maximum balloon diameter to the 
valve area, a lower device:annulus area ratio, and a lower device:LVOT area ratio (Table 2). 
Patients with ≥mild PVL were also more likely to have a less deep implantation; this difference 
was statistically significant when measured from the left coronary sinus, but not when measured 
from the non-coronary sinus. The degree of valve oversizing in relation to both the annulus and 
LVOT was significantly correlated with a decreased rate of PVL (Table 2). Valve repositioning 
or retrieval during implantation and measured waist (defined as minimum valve diameter divided 
by maximum valve diameter) were not significantly different between patients with and without 
PVL. 
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Mortality was not significantly different between groups in this analysis. Kaplan-Meier 
rates of all-cause mortality at 1 year were 87.0% in patients with ≥mild PVL versus 91.7% in 
patients with none/trace PVL (log-rank P=0.41), although it should be noted that this comparison 
is underpowered. 
Significant independent predictors of ≥mild PVL by multivariate analysis were the 
annulus area, the ratio of the device area to the annulus area, and LVOT calcium volume (Table 
3). Leaflet and annulus calcium volume trended towards being an independent predictor of ≥mild 
PVL, but the difference did not reach statistical significance (P=0.06). Medically treated 
hyperlipidemia was also a significant independent predictor of decreased PVL (P=0.01).  
The correlation between various levels of valve oversizing in relation to the annulus and 
the rate of ≥mild PVL is shown in Figure 4. When the valve was undersized (ie, nominal valve 
area less than the annular area), the rate of ≥mild PVL was 53.1%. In contrast, slight oversizing 
of the valve (0% to 5%) resulted in a ≥mild PVL rate of 17.5%. Above 5%, there appeared to be 
a plateau effect, with the rate of ≥mild PVL remaining at ~3% for both 5% to 10% and ≥10% 
annular overstretch. 
The correlation between various levels of valve oversizing and the rate of permanent 
pacemaker implantation is shown in Figure 5. The pacemaker rate trended higher when 
oversizing of the valve in relation to the annulus was ≥10% (38.5% (25/65) vs 25.5% (47/184), 
P=0.2), although this did not reach statistical significance. The pacing rate was more closely 
correlated with oversizing in relation to the LVOT, with a significantly higher rate when the 
valve was ≥10% bigger than the LVOT by area (37.4% (43/115) vs 21.6% (29/134), P=0.05). 
Discussion 
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In the REPRISE II Trial Extended Cohort, overall rates of PVL with the Lotus valve were 
very low, with 86% of patients having no or trace PVL, as assessed by an independent core lab. 
Significant independent predictors of mild/moderate PVL included the ratio of device area to 
annulus area, LVOT calcium volume, and annulus area. When the nominal valve area was 
smaller than the annulus, i.e. device:annulus area ratio <1, the rate of mild or moderate 
paravalvular regurgitation was 53.1%. The rates of mild/moderate paravalvular regurgitation 
with 0-5%, 5-10%, and >10% annular oversizing by area were 17.5%, 2.9%, and 3.2%, 
respectively, suggesting that optimal valve oversizing to minimize PVL is >5% by area. While 
sizing was universally performed using CT in this study, trans-esophageal echocardiography 
(TEE) including 3D TEE could also be employed. 
General predictors of PVL following TAVR have been previously identified as 
annulus/device size mismatch3-5; TAVR access route5,11; annulus eccentricity2; calcification in 
the annulus, leaflets or LVOT3,12; device implantation depth3,4; valve post-dilatation13; moderate 
baseline aortic or mitral regurgitation4,5,13; baseline atrial fibrillation5; and the use of CoreValve 
versus Sapien/Sapien XT3-5,13,14. In studies of valve-specific PVL predictors, predictors of PVL 
following CoreValve implantation include LVOT diameter,15 annulus/device size mismatch,15,16 
and depth of implantation.15,16 For the Edwards Sapien valves (Sapien, Sapien XT, Sapien 3), 
significant predictors of PVL include size mismatch6,17,18 and annular/leaflet/LVOT 
calcification.6,17-19  
The mechanism for the contribution of annulus/valve size mismatch to the development 
of PVL is intuitive; moreover, overall annulus or LVOT size as independent predictors are likely 
to be related to size mismatch given that all valve manufacturers have only a discrete number of 
valve sizes available. Depth of implantation with CoreValve is likely related to PVL by also 
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affecting the annulus/valve diameter ratio, given the conical nature of the device.16 In the current 
analysis, annulus/size mismatch and annulus size also emerged as independent predictors of PVL 
for the Lotus Valve, a finding that was likely exacerbated by the fact that only 2 valve sizes 
(23mm and 27mm) were available for the study. Data from the RESPOND registry, in which a 
25mm valve was also available, demonstrated even lower rates of PVL with Lotus, with mild or 
greater PVL in only 8.0% of patients, potentially reflecting the ability to select a more optimal 
valve size across a greater range of patient anatomies.20 Specifically, in the REPRISE II cohort, a 
number of patients with annular diameters above 23mm were treated with an undersized 23mm 
Lotus, increasing the risk of PVL. Balloon pre-dilatation was less frequently performed in the 
RESPOND registry than in this study (53.9% vs 100% in REPRISE II Extension), though how 
this might have impacted on the relative rates of PVL is less clear.    
In contrast, annulus eccentricity and calcification contribute to PVL by preventing full 
apposition of the device against the aortic wall, allowing the development of paravalvular jets. 
The Adaptive Seal of the Lotus Valve was developed to address this issue and the Lotus valve 
has the lowest reported PVL rates of currently available valves, although even with the Adaptive 
Seal, calcification continues to remain a significant predictor of PVL. We found that calcium in 
the LVOT was a stronger predictor of PVL than was annular calcium. This raises the possibility 
that sealing in the LVOT may be more important than sealing at the level of the annulus and 
leaflets. Patients with ≥mild PVL did have a less deep implant (5.2±2.7mm) than those without 
(6.7±2.8mm; P=0.007), although depth of implant did not emerge as an independent predictor of 
PVL. It is unclear why hyperlipidemia or its treatment would be a preventative factor for PVL 
with Lotus. This finding will require further evaluation in larger studies including the ongoing 
REPRISE III pivotal trial.    
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Based on this study and others reported in the literature, optimal valve sizing for the 
prevention of PVL varies according to valve type. With all transcatheter valves, undersizing 
results in significantly increased PVL, leaving in question the appropriate degree of oversizing 
for each. With the Lotus valve, the current results imply that 5% to 10% oversizing results in 
~3% ≥mild PVL, with no further benefit in terms of PVL with oversizing greater than 10% by 
area, suggesting that minimal oversizing of the Lotus valve is needed to prevent PVL. In 
contrast, for Sapien 3, 5% to 10% oversizing has been suggested as the optimal sizing and is 
associated with 13.3% ≥mild PVL6; similarly, for Sapien XT, >10% oversizing was associated 
with ≥20% mild PVL).6 Although valve sizing has not been studied in terms of mild or greater 
PVL for CoreValve, one study has noted that 15% to 25% oversizing of the valve was associated 
with the lowest rates of PVL, resulting in ≥6.3% rates of moderate PVL.21  
It is important to note that oversizing of a TAVR valve in relation to the LVOT and/or 
annulus diameters has also been associated with an increased need for a permanent 
pacemaker,22,23 which implies there is a need to balance the degree of oversizing to prevent these 
two different adverse outcomes (PVL or pacemaker). This analysis found that the permanent 
pacemaker rate increased with valve oversizing of ≥10% in relation to the annulus, although this 
finding was not statistically significant; there was no difference in pacing rate with sizing ratios 
below this threshold. This strongly suggests that optimal oversizing of the Lotus valve to 
minimize risk of both PVL and pacemaker rate is 5-10%. It should be noted, however, that 
frequency of permanent pacemaker implantation is more closely correlated with overstretch in 
the LVOT, and that although annular rupture due to oversizing was not observed in the 
REPRISE II study plus Extended Cohort, it has been reported in approximately 0.3% to 0.8% of 
patients undergoing TAVR.24  
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This study has the usual limitations implicit in a single-arm, open-label study; however, a 
key strength was that all angiographic and echocardiography results from this trial were 
adjudicated by independent core labs. As noted previously for the REPRISE II study,25 only two 
valve sizes (23mm and 27mm) were available at the time of the study, while a 25mm valve is 
now also available in clinical practice. The reduced rate of echocardiographic follow-up 
compared with clinical follow-up is also a common limitation in current TAVR trials,26 which 
was addressed in this analysis by using discharge data where 30-day information was not 
available. Further, the limitations of TTE itself in assessing PVL must be considered 27; however, 
this is the standard for all published valve studies and therefore is broadly applicable. Finally, the 
rate of mild or greater PVL with the Lotus Valve is <15%, meaning that the analysis population 
for predictors of PVL in this study is relatively small and these results should be regarded as 
hypothesis-generating until confirmed in a larger trial. 
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Figure Titles and Legends 
Figure 1. The Lotus Valve  
Figure 2. Study Flow 
Figure 3. Aortic regurgitation over time.  
Figure 4. Effect of valve sizing on paravalvular leak. Overstretch was defined as the nominal 
valve area divided by the annular area. 
Figure 5. Effect of valve sizing on newly implanted permanent pacemaker (PPM) through 
30 days. A) Rate of new PPM by annulus overstretch; B) Rate of new PPM by left ventricular 
outflow tract (LVOT) overstretch. Overstretch was defined as the nominal valve area divided by 
the annular or LVOT area. 
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Table 1. Baseline Patient and Anatomical Characteristics 
Variable 
          Paravalvular 
None/Trace  
(n=197) 
Leak  
≥Mild         
(n=32) 
P value 
Age (years) 84 ± 5 (197) 86 ± 5 (32) 0.048 
Woman 93/197 (47%)  22/32 (69%)  0.02 
STS Score (v2.73) (%) 6.2 ± 3.8 (197) 6.8 ± 4.6 (32) 0.46 
Treated diabetes mellitus 55/197 (28%)  4/32 (13%)  0.06 
Treated hypertension 152/197 (77%)  23/32 (72%)  0.51 
Treated hyperlipidemia 121/197 (61%)  13/32 (41%)  0.03 
Prior coronary artery disease 104/197 (53%)  14/32 (44%)  0.34 
Prior cerebral vascular accident 13/197 (7%)  3/32 (9%)  0.47 
Baseline LVEF (%) 53 ± 10 (99) 54 ± 13 (18) 0.76 
Baseline atrial fibrillation 41/196 (21%)  8/32 (25%)  0.60 
Pre-procedure aortic regurgitation (any) 137/175 (78%)  23/29 (79%)  0.90 
Pre-procedure mean aortic gradient (mmHg) 44 ± 13 (170) 53 ± 15 (29) <0.001 
Annulus diameter (mm)* 24 ± 2 (196) 24 ± 2 (32) 0.84 
Annulus area (mm2) 444 ± 74 (196) 444 ± 55 (32) 0.96 
Annulus eccentricity† 0.8 ± 0.1 (196) 0.8 ± 0.1 (32) 0.65 
LVOT diameter (mm)* 23 ± 2 (196) 23 ± 2 (32) 0.80 
LVOT area (mm2) 423 ± 81 (196) 417 ± 61 (32) 0.72 
LVOT eccentricity† 0.7 ± 0.1 (196) 0.7 ± 0.1 (32) 0.65 
Total LVOT calcium volume (mm3) 22 ± 43 (196) 71 ± 94 (32) 0.008 
Total leaflet & annulus calcium volume 
(mm3) 
836 ± 589 (196) 1109 ± 620 (32) 0.02 
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Right coronary cusp leaflet/annulus calcium 
volume (mm3) 
229 ± 163 (196) 307 ± 217 (32) 0.06 
   Left coronary cusp leaflet/annulus calcium 
volume (mm3) 
285 ± 427 (196) 381 ± 233 (32) 0.07 
   Non-coronary cusp leaflet/annulus calcium 
volume (mm3) 
322 ± 209 (196) 421 ± 303 (32) 0.08 
Values are mean ± standard deviation (n) or n/N (percent). Anatomic characteristics assessed by 
independent core laboratory angiographic analysis. 
*Area-derived 
†Eccentricity defined as perpendicular to the maximum annulus diameter divided by the maximum 
annulus diameter. 
Abbreviations: LVEF=left ventricular ejection fraction; LVOT=left ventricular outflow tract; 
STS=Society of Thoracic Surgeons 
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Table 2. Procedural Characteristics 
Variable 
        Paravalvular 
None/Trace  
(n=197) 
Leak 
≥Mild          (n=32) 
P value 
Valve size implanted (mm)    
   23 79/197 (40%)  24/32 (75%)  <0.001 
   27 118/197 (60%)  8/32 (25%)  <0.001 
Valve repositioned or retrieved 78/197 (40%) 10/32 (31%)  0.37 
Maximum balloon diameter:valve area ratio 0.9 ± 0.1 (196) 0.8 ± 0.1 (32) 0.004 
Measured waist reduction [min/max] (%)* 12.2 ± 4.8 (91) 13.0 ± 4.9 (17) 0.53 
Depth of device implantation, left coronary sinus 
(mm) 
6.7 ± 2.8 (173) 5.2 ± 2.7 (28) 0.007 
Depth of device implantation, non-coronary sinus 
(mm) 
5.1 ± 2.5 (171) 4.7 ± 2.8 (27) 0.52 
Device area : Annulus area ratio 1.2 ± 0.1 (196) 1.0 ± 0.1 (32) <0.001 
Annulus overstretch†‡    
Any (>0%) 181/196 (92%)  15/32 (47%)  <0.001 
≥5% 129/196 (66%)  4/32 (12.5%)  <0.001 
≥10% 61/196 (31%)  2/32 (6.3%)  0.004 
Device area:LVOT area ratio 1.2 ± 0.2 (196) 1.1 ± 0.2 (32) <0.001 
LVOT overstretch†‡    
Any (>0%) 181/196 (92%)  22/32 (69%)  <0.001 
≥5% 141/196 (72%)  13/32 (41%)  <0.001 
≥10% 95/196 (49%)  8/32 (25%)  0.01 
Values are mean ± standard deviation (n) or n/N (percent). Anatomic characteristics assessed by independent core 
laboratory angiographic analysis. 
*Defined as minimum valve diameter divided by maximum valve diameter 
†Area-derived 
‡Overstretch defined as the nominal valve area divided by the LVOT or annular area. 
Abbreviations: LVOT=left ventricular outflow tract 
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Table 3. Multivariate Predictors of ≥Mild Paravalvular Leak 
Variable Odds Ratio 95% CI P value 
Ratio of device area to annulus area (%) 0.87 0.83, 0.92 <0.001 
Annulus area (per 10 mm2) 0.89 0.82, 0.96 0.002 
Treated hyperlipidemia 0.29 0.11, 0.74 0.01 
LVOT calcium volume (per 100mm3) 2.85 1.44, 5.63 0.03 
Leaflet & annulus calcium volume (per 100mm3) 1.07 1.00, 1.16 0.06 
Abbreviations: CI=confidence intervals; LVOT=left ventricular outflow tract 
 
 
